Articles related to IMMUNOTHERAPY

The TOPAZ-1 trial demonstrates that adding durvalumab to standard chemotherapy significantly improves overall survival in patients with advanced biliary tract cancer, potentially establishing a new first-line treatment option for this difficult-to-treat malignancy.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

Recent findings suggest that a slow up-dosing strategy in peanut oral immunotherapy for young children may offer a safer and more effective approach to managing peanut allergies.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.

Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.